18/03/2026 J&J announced FDA approval for icotrokinra for adult and pediatric patients with moderate to severe plaque psoriasis J&J announced FDA approval for icotrokinra for adult and pediatric patients with moderate to severe plaque psoriasis ( Ref ) Johnson & Johnson announced that the US FDA had approved ICOTYDE™ (icotrokinra; IL-23 receptor antagonist) for the treatment of adults and pediatric patients aged 12 years and older who weighed at least 40 kg with moderate to s